A Phase II Study of Hsp90 Inhibitor AUY922 for the Treatment of Patients with Refractory Gastrointestinal Stromal Tumor
Diseases and Conditions Researched
Cancer; Other Digestive Organ
What is the purpose of this trial?
To determine the progression-free survival (PFS) of patients with refractory GIST treated with AUY922.
Click here for detailed participation information for this trial.
|Sponsor:||Sarah Cannon Research Institute Oncology Research Consortium|
How will my information be used?
When you express interest in a specific study, the information from your profile will be sent to the doctor conducting that study. If you're eligible to participate, you may be contacted by a nurse or study coordinator.
If you select a health category rather than a specific study, doctors who have active studies in that area may contact you to ask if you would like to participate.
In both cases, you will be contacted by the preferred method (email or phone) that you specified in your profile.